公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | TAI-CHUNG TSENG ; Peng C.-Y; Hsu Y.-C; TUNG-HUNG SU ; Wang C.-C; CHUN-JEN LIU ; HUNG-CHIH YANG ; Yang W.-T; Lin C.-H; Yu M.-L; Lai H.-C; Tanaka Y; Nguyen M.H; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Liver Cancer | 17 | 13 | |
2005 | Biliary hamartomas with delayed 99mTc-diisopropyl iminodiacetic acid clearance | CHEN-HUA LIU ; RUOH-FANG YEN ; KAO-LANG LIU ; YUNG-MING JENG ; Pan M.-H.; PEI-MING YANG | Journal of Gastroenterology | 2 | 4 | |
2019 | Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma | TUNG-HUNG SU ; CHUN-JEN LIU ; TAI-CHUNG TSENG ; Chou S.-W; CHEN-HUA LIU ; HUNG-CHIH YANG ; SHANG-JU WU ; PEI-JER CHEN ; DING-SHINN CHEN ; CHI-LING CHEN ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 29 | 26 | |
2014 | Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously | Cheng H.-R.; JIA-HORNG KAO ; Wu H.-L.; Chen T.-C.; TAI-CHUNG TSENG ; CHEN-HUA LIU ; TUNG-HUNG SU ; PEI-JER CHEN ; DING-SHINN CHEN ; CHUN-JEN LIU | Liver International | 13 | 11 | |
2017 | Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients | Lee M.-H.; Huang C.-F; Lai H.-C; Lin C.-Y; Dai C.-Y; CHUN-JEN LIU ; Wang J.-H; Huang J.-F; Su W.-P; HUNG-CHIH YANG ; Kee K.-M; Yeh M.-L; Chuang P.-H; SHIH-JER HSU ; Huang C.-I; JIA-HORNG KAO ; CHIEH-CHANG CHEN ; Chen S.-H; Jeng W.-J; Yang H.-I; Yuan Y; Lu S.-N; Sheen I.-S; CHEN-HUA LIU ; Peng C.-Y; Yu M.-L; Chuang W.-L; Chen C.-J. | Scientific Reports | 16 | 14 | |
2014 | Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy | TUNG-HUNG SU ; CHUN-JEN LIU ; HUNG-CHIH YANG ; YUNG-MING JENG ; Cheng H.-R; CHEN-HUA LIU ; TAI-CHUNG TSENG ; THAI-YEN LING ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Gastroenterology | 16 | 14 | |
2015 | Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection | Cheng H.-R.; JIA-HORNG KAO ; Wu H.-L; TAI-CHUNG TSENG ; CHEN-HUA LIU ; HUNG-CHIH YANG ; TUNG-HUNG SU ; PEI-JER CHEN ; DING-SHINN CHEN ; CHUN-JEN LIU | Hepatology International | 14 | 11 | |
2018 | Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 41 | 41 | |
2015 | Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping | CHEN-HUA LIU ; Liang C.-C; CHUN-JEN LIU ; Lin C.-L; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Clinical Microbiology | 58 | 55 | |
2012 | Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load | TAI-CHUNG TSENG ; CHUN-JEN LIU ; HUNG-CHIH YANG ; TUNG-HUNG SU ; Wang C.-C; CHI-LING CHEN ; Fang-Tzu Kuo S; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology | 129 | 115 | |
2019 | Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium | Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; CHEN-HUA LIU ; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO ; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators | Hepatology International | 31 | 27 | |
2023 | Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B | SHANG-CHIN HUANG ; TUNG-HUNG SU ; TAI-CHUNG TSENG ; CHI-LING CHEN ; SHIH-JER HSU ; SIH-HAN LIAO ; CHUN-MING HONG ; CHEN-HUA LIU ; Lan, Ting-Yuan; HUNG-CHIH YANG ; CHUN-JEN LIU ; PEI-JER CHEN ; JIA-HORNG KAO | Hepatology international | 5 | 2 | |
2013 | Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion | HUNG-CHIH YANG ; CHI-LING CHEN ; Shen Y.-C; Peng C.-Y; CHUN-JEN LIU ; TAI-CHUNG TSENG ; TUNG-HUNG SU ; Chuang W.-L; Yu M.-L; Dai C.-Y; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology | 43 | 37 | |
2018 | Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy | TUNG-HUNG SU ; HUNG-CHIH YANG ; TAI-CHUNG TSENG ; JYH-MING LIOU ; CHEN-HUA LIU ; CHI-LING CHEN ; PEI-JER CHEN ; DING-SHINN CHEN ; CHUN-JEN LIU ; JIA-HORNG KAO | Journal of Infectious Diseases | 57 | 52 | |
2019 | Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection | TUNG-HUNG SU ; CHUN-JEN LIU ; TAI-CHUNG TSENG ; Chou S.-W; CHEN-HUA LIU ; HUNG-CHIH YANG ; SHANG-JU WU ; PEI-JER CHEN ; DING-SHINN CHEN ; CHI-LING CHEN ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 10 | 9 | |
2019 | Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
2019 | Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction? | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
2023 | Editorial: Noninvasive tests for metabolic dysfunction-associated steatotic liver disease: A refinement of the Nash-FibroTest for type 2 diabetes mellitus | CHEN-HUA LIU | Alimentary pharmacology & therapeutics | |||
2011 | Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy | TAI-CHUNG TSENG ; Yu M.-L.; CHUN-JEN LIU ; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU ; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Antiviral Therapy | 76 | 70 | |
2011 | Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: Genotype B vs C | CHUN-JEN LIU ; Cheng H.-R.; Chen C.-L.; Chen T.-C.; TAI-CHUNG TSENG ; Wang Z.-L.; PEI-JER CHEN ; CHEN-HUA LIU ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Viral Hepatitis | 20 | 19 |